Acute Lymphoblastic Leukaemia: ESMO Clinical Practice Guidelines

Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v69-v82 
Authors: D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. M. Ribera and C. Buske

The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations. This figure qualifies ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. The new ESMO Clinical Practice Guidelines provide up-to-date information on the management of acute lymphoblastic leukaemia, and include recommendations for diagnosis and pathology/molecular biology, staging and risk assessment as well as detailed treatment strategies for early and advanced disease.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings